Pullback in pharma has created a compelling buying opportunity
The fundamentals are good for the health care sector in general. Recent news articles on drug pricing/gouging are not likely to effect meaningful change for the overall group dynamics in my opinion or that any changes may be long time in coming and tempered far below market expectations. It’s true that it may compress multiple prices for a while as Evercore #1 ranked biotech analyst Mark Schoenebaum said on CNBC today but I agree with him, its really about innovation. His favorite picks are Gilead GILD and maintains a price target of $115 on the stock. I am not as enthusiastic … Read more